Asia Pacific Veterinary Vaccines Market Report and Forecast 2024-2032

Asia Pacific Veterinary Vaccines Market Size

The market size for veterinary vaccines in the Asia Pacific reached a value of more than USD 2.06 billion in 2023. The Asia Pacific veterinary vaccines market is expected to grow at a CAGR of 6.6% between 2024 and 2032, reaching a value of USD 3.66 billion by 2032. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

Veterinary vaccines are specialised vaccines designed for animals to protect them against diseases or infections that they may be susceptible to. Veterinary vaccines with living organisms are preferred because they give the best protective response over purified antigens which are incapable of growing and spreading in the host. 

Asia has a large number of livestock such as pigs, poultry, and cattle, which has opened opportunities for the Asia Pacific veterinary vaccines market to grow. Extreme care and protection from a number of diseases is required to avoid loss in business. 

Government agencies across multiple countries in the region are taking up steps for the protection of animals and preventing the spread of diseases. They are carrying out campaigns informing people of diseases and vaccination programmes for farm animals and pets. 

Key players are investing their time and money in research and development for new oral as well as parental techniques to inject vaccines in domestic and wild animals in order to encourage a healthy lifestyle in animals and prevent diseases that may be transmitted to humans. 

Asia Pacific Veterinary Vaccines Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on vaccine type, the Asia Pacific veterinary vaccines market can be divided into livestock vaccines, companion animal vaccines, and other types of vaccines. Livestock vaccines are further subdivided into porcine vaccines, bovine vaccines, and poultry vaccines, among others, while companion animal vaccines are subdivided into canine vaccines, feline vaccines, and equine vaccines, among others.

On the basis of route of administration, the market is divided into oral, parenteral, and others. By distributional channel, the market is segmented into veterinary hospitals and clinics, pharmacies and drug stores, and online, among others. Based on country, the market is segmented into China, Japan, India, South Korea, Indonesia, Thailand, and Australia, among others.  

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the Asia Pacific veterinary vaccines market covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.  

• Boehringer Ingelheim International GmbH

• Elanco Animal Health Inc.

• Zoetis Services LLC

• Merck & Co., Inc.

• Ceva Sante Animale

• Hester Biosciences Limited

• QYH Biotech Co., Ltd.

• Kyoto Biken Laboratories, Inc.

• PT JAPFA COMFEED INDONESIA Tbk

• Medion Farma

• Zuellig Pharma Limited

• PT Kalbe Farma Tbk

• Others

Market Share by Vaccine Type

Livestock vaccines account for a leading share in the Asia Pacific veterinary vaccines market due to the vast presence of livestock. With specialised vaccines available based on the animal type, they are an easy way to prevent illnesses in animals such as cattle, pigs, and poultry. Unexpected illnesses can spread quickly among livestock, causing significant loss of life and damage to the earning potential of the owners. Rapid spread of diseases amongst animals increases the risk of mutations, which may affect humans. 

Although there is an increase in the number of companion animals adopted by people in the Asia Pacific as pets, the number of pets remains relatively lower as compared to other countries and regions. With growing awareness regarding the health of pets, and government regulations requiring vaccinations of pets, the companion animals segment is expected to witness steady growth in the coming years. 

Market Share by Route of Administration

Vaccines in animals is commonly administered by injecting the vaccines in them through their skin in a mode commonly known as parenteral vaccination. Injecting vaccines offers multiple benefits, including confirmation that the vaccine has been administered effectively as animals may spit out oral vaccines. Due to the ease and accuracy of vaccine injections, parenteral administration holds a significant share in the Asia Pacific veterinary vaccines market. 

Oral vaccinations, in comparison, are often preferred for companion animals as the pet owners can monitor administration and there is less stress on the animal. With time, there are new developments into other methods of vaccination, including through food and mucosal vaccination which are proving efficient and are expected to increase in demand in the coming years. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape of Asia Pacific Veterinary Vaccines Industry

Boehringer Ingelheim International GmbH is a research-based pharmaceutical company which manufactures and delivers healthcare products such as medicines and vaccines. It was founded in 1885 and its headquarter is situated in Germany. 

Elanco Animal Health Inc. is a pharmaceutical company which has its headquarters in Indiana, United States. It was found in 1954 with an aim to deliver vaccines and medicines for pets and domestic animals. 

Zoetis Services LLC established in 1952 is a healthcare company founded specifically for animal care. It is based out of New Jersey, United States and has a strong presence in the Asia Pacific veterinary vaccines market. They serve their consumers with the premium quality vaccines, medicines, and diagnostic products. 

Other market players include Merck & Co., Inc., Ceva Sante Animale, Hester Biosciences Limited, QYH Biotech Co., Ltd., Kyoto Biken Laboratories, Inc., PT JAPFA COMFEED INDONESIA Tbk, Medion Farma, Zuellig Pharma Limited, and PT Kalbe Farma Tbk, among others.

Key Highlights of the Report